Platform enables precise, efficient delivery of genetic medicines in vivo
October 17, 2022 -- Biotech company Homology Medicines is leveraging 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo via gene therapy or nuclease-free gene editing modality. CEO Albert Seymour spoke with Science Advisory Board about their platform. Read More
Manufacturing remains big challenge for cell and gene therapy industry
October 17, 2022 -- Science Advisory Board spoke with Eric Blair, chief commercial officer for Andelyn Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa about the challenges of manufacturing to meet growing demand in the cell and gene therapy industry. Read More
Gene editing advances continue a pace, but progress is still early: panel
October 17, 2022 -- With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa say they are looking forward to other near- and longer-term breakthrough technologies on the horizon. Read More
Roadblocks continue to hamper CGT companies as they look to commercialize their products
October 14, 2022 -- The cell and gene therapy (CGT) sector will continue to face investment and regulator challenges in the near term. That’s the consensus of companies in the space who participated in a workshop at this week’s Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
FDA biologics chief outlines ways to remove barriers to cell and gene therapies
October 13, 2022 -- At this year's Meeting on the Mesa, the U.S. Food and Drug Administration’s top biologics regulator said the use of a “cookbook” for developing cell and gene therapy products and global regulatory convergence could help to facilitate their development and take them to the next level. Read More
New ARM CEO provides vision for cell and gene therapy sector, need to address stakeholder concerns
October 12, 2022 -- Timothy Hunt, the new CEO of the Alliance for Regenerative Medicine (ARM), kicked off the 2022 Cell & Gene Meeting on the Mesa, laying out his vision for the industry and emphasizing the need to engage all major stakeholders. Read More
Panel to focus on pluripotent stem cells at Cell & Gene Meeting on the Mesa
October 11, 2022 -- A panel on October 13 at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, will focus on new pluripotent stem cell (PSC) developments and advancements as well as the challenges of scaling up PSC-derived cell therapies. Read More
Gene therapy one step closer to delivery across blood-brain barrier: study
October 11, 2022 -- Brigham and Women’s Hospital researchers say the rational design of adeno-associated viruses has generated gene therapy delivery vectors that are better at crossing the blood-brain barrier to treat diseases of the central nervous system. Read More
6 startups to compete for $250K grand prize at 2022 BioTools Innovator capstone event
October 10, 2022 -- BioTools Innovator will hold its 2022 capstone event on October 13 in Carlsbad, CA, collocated with the Cell & Gene Meeting on the Mesa. Read More
Cytiva acquires Cevec Pharmaceuticals to boost cell line development
October 10, 2022 -- Life sciences company Cytiva has acquired Cevec Pharmaceuticals for an undisclosed amount, which will further strengthen Cytiva's cell line development, according to the companies. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
